Machine Learning in High-Stakes Decisions
As Machine Learning & AI have become more universal, there are uses at the extremes of decisions in healthcare, mental health & crisis planning that will define how much we can rely on computers to make critical decisions. Come learn from some companies operating at this technology front.
Chris Gibson, PhD, is the Co-founder and CEO of Recursion Pharmaceuticals, a biotech company leveraging the latest in automation, artificial intelligence and biology to do drug discovery at scale. Chris developed the technology and approach that seeded Recursion as part of his MD/PhD graduate work in the lab of Co-Founder Dr. Dean Li at the University of Utah. Chris left medical school to transform this technology into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and management, as well as a graduate of an intense entrepreneurship course at Stanford GSB. He is a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia, and a member of the Rare and Undiagnosed Network Advisory Board. Outside of work, Chris enjoys cycling on both the road and the trails that cut through Utah's great wilderness, as well as spending time with family.
Dr. Noah Craft MD, PhD is the co-founder and CEO of Science 37 and a physician-scientist-entrepreneur. Science 37 transforms the clinical research process, accelerating biomedical discovery and reducing clinical trial costs by shifting the center for research from traditional institutional investigative sites to the patient's home and local healthcare system. We use our patient-centered technology platform (NORA®) to create metasites™, simplify the process of participating in trials, and connect patients safely and securely to the world's best scientists, no matter where they live. For 10+ years, Dr. Craft has worked on the skin microbiome, parasite immunology, and cancer vaccine development. He serves as a Senior Strategic Advisor to both VisualDx and Direct Derm and is on the Board of Directors at BioGraph 55. He has published more than 45 peer-reviewed research manuscripts and holds multiple patents. Dr. Craft received a B.S. from Brown University, completed medical school, graduate school, residency, and post-doctoral research at UCLA.
Omid Toloui is Vice President of Digital Health Strategy & Alliances at CareMore Health, a health plan, care delivery system and subsidiary of Anthem, Inc. Omid leads the company's digital innovation efforts, which seek to identify and implement leading-edge programs, partnerships and/or technologies that improve outcomes for patients and address the needs of the health system and its clinicians. Previously, Omid was at Altegra Health (acquired by Emdeon) where he led the growth and development of its portfolio of analytics and technology-driven engagement solutions aimed at improving quality, increasing access to care and encouraging patients to take a more active role in their health. Omid earned his MBA, MPH and B.S. degrees from UCLA.
Kara joined Upfront as a partner in November 2014. Before joining Upfront, Kara co-founded Moonfrye, a children’s e-commerce company which merged to become Seedling. Prior to Seedling, Kara spent close to seven years at IAC where she acted as the Senior Vice President and General Manager of Urbanspoon and Citysearch. Prior to Urbanspoon/Citysearch, Kara co-headed the M&A group at IAC where she lead some of their most successful acquisitions, notably Urbanspoon, Dictionary.com and Aston Hotels. While at IAC, Kara also served as a board member to Hatch Labs, IAC’s mobile technology incubator, where she was the seed investor and advisor to Tinder. Kara also spent time at Morgan Stanley, Microsoft, and Battery Ventures.